CANDiT: A machine learning framework for differentiation therapy in colorectal cancer

Saptarshi Sinha1, Joshua Alcantara2, Kevin Perry2

  • 1Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

Cell Reports. Medicine
|October 21, 2025
PubMed

Insights

A new machine learning framework, CANDiT, identifies PRKAB1 as a target to eliminate colorectal cancer stem cells (CSCs). Activating this target promotes differentiation, reducing recurrence and mortality risk in cancer patients.

Area of Science:

  • Oncology
  • Computational Biology
  • Molecular Biology

Background:

  • Cancer stem cells (CSCs) are a therapeutic challenge due to their resistance to conventional treatments.
  • Reactivating cell differentiation is a promising strategy to eliminate CSCs.
  • Colorectal cancer (CRC) often involves the loss of key lineage factors like CDX2 in aggressive subtypes.

Purpose of the Study:

  • To develop a machine learning framework (CANDiT) for identifying therapeutic targets to induce CSC differentiation in CRC.
  • To identify specific molecular vulnerabilities associated with CSCs in CRC.
  • To evaluate the therapeutic potential of targeting identified vulnerabilities for CSC elimination.

Main Methods:

  • Development of CANDiT, a machine learning framework analyzing transcriptomic data to find differentiation vulnerabilities.
  • Identification of PRKAB1, a stress polarity sensor, as a key target, particularly in CDX2-low CRC cells.
  • Testing a PRKAB1 agonist in various CRC models (cell lines, xenografts, patient-derived organoids).

Main Results:

  • The PRKAB1 agonist successfully reactivated intestinal lineage programs and dismantled stemness pathways (Wnt/YAP).
  • Selective elimination of CDX2-low CSCs was observed across all tested CRC models.
  • A strong therapeutic index was linked to the CDX2-low CSC state.
  • A 50-gene predictive signature indicated a potential ~50% reduction in CRC recurrence and mortality risk.

Conclusions:

  • CANDiT provides a precision framework for targeting CSCs by inducing lineage restoration.
  • PRKAB1 activation represents a viable therapeutic strategy for eliminating CSCs in CRC.
  • The identified gene signature may predict treatment response and patient outcomes in CRC.